Ministry of Health of Russia has granted Natsimbio Holding an authorization to conduct clinical trials of the first in Russia and the second in the world combined vaccine for the prevention of influenza and coronavirus infection - Ultrix Combi. Safety and tolerability of the drug will be tested with the participation of 370 patients. Drug is being developed by Natsimbio in cooperation with Artgen Biotech.